#United States #Tampa #Psilera #PSIL-006 #neuroplastogen

Psilera Inc. Secures $8.8 Million in Funding

Psilera Inc., a trailblazer in the biopharmaceutical sector, has successfully raised $8.8 million in an oversubscribed Series Seed funding extension. This funding, primarily led by a diverse group of institutional and strategic investors, will play a crucial role in facilitating the clinical development of the company's flagship neuroplastogen, PSIL-006. The objective is to propel PSIL-006 towards its first-in-human trials slated for 2027.

Dr. Chris Witowski, the Co-Founder and CEO of Psilera, expressed enthusiasm about this funding milestone. He stated, "This funding marks a pivotal inflection point for Psilera. With the continued support of our investors, we are now fully resourced to transition from a discovery-stage research company to a clinical-stage organization. Our mission is to provide safe, effective, and accessible treatments for patients suffering from a range of neurological conditions, and this capital ensures we remain on track for our first-in-human trials in 2027."

PSIL-006 is touted as a groundbreaking neuroplastogen meticulously designed to harness the therapeutic advantages of traditional psychedelics while effectively minimizing hallucinogenic effects and cardiovascular risks. This innovative compound aims to address significant unmet medical needs in the neuroscience domain.

The recent funding round comes on the heels of several key milestones achieved by Psilera, indicating its growing influence in the sector. These milestones include:

• - The recruitment of Dr. Magali Haas, a distinguished expert in neuroscience, as Chief Medical Officer. Dr. Haas brings invaluable experience which will aid in steering the company's clinical developments.
• - An impressive NIH funding award of up to $2 million aimed at supporting IND-enabling studies on PSIL-006 concerning alcohol use disorders.
• - A strategic licensing agreement with atai Life Sciences, which enhances Psilera's portfolio with access to its DMT patent assets.

Dr. Witowski further commented on the recent U.S. Executive Order titled 'Accelerating Medical Treatments for Serious Mental Illness,' which underscores a renewed federal commitment to increasing access to psychedelic substances for therapeutic use. "With the renewed focus from key regulatory agencies, we look forward to working with them to fully develop PSIL-006," said Witowski. This governmental support sets a positive tone for further research and application of psychedelic therapies, significantly impacting the future landscape of medical treatments.

As Psilera continues its journey, the company remains dedicated to scientific excellence and patient access. Its innovative approach to neuropharmacology aims at revolutionizing the treatment of neurological conditions, bolstering the promise of life-changing therapies for individuals struggling with various psychological and emotional disorders. As more stakeholders and the scientific community recognize the potential of psychedelics, Psilera positions itself at the forefront of this transformative movement.

To learn more about Psilera and its innovative therapeutic solutions, please visit www.psilera.com.